News
Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led ...
Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially ...
Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) ...
Moisturizers containing hormones like estrogen are trending again, with promises of firmer, younger-looking skin through ...
This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with major updates for antibody-drug conjugates, HER2-positive regimens, and ...
Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results